COMPARE · Reviewed July 30, 2026
CDNA vs NBIX
Verdict: Side-by-side breakdown using the Bull Rankings model. CDNA scored 83.8, NBIX scored 87.2 — NBIX leads.
Compare another set
CDNA
CareDx, Inc.
83.8
$38.10 · $2.0B
fundamentals as of
Score gap
3.4
NBIX leads
NBIX
Neurocrine Biosciences, Inc.
87.2
$185.50 · $18.7B
fundamentals as of
The model, pillar by pillar (0–100 each)
CDNA
stronger →← stronger
NBIX
88
Qualityreturns · margins · balance sheet
82
94
Growthrevenue & earnings expansion
100
72
Valuevaluation vs sector peers
80
NBIX is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
CDNA
NBIX
$92mC-
FCF
$831mC+
+34.4%A
Rev
+28.6%A-
0.08B+
D/E
0.14B+
4.3xB
P/S
—
—
PEG
0.51A-
—
P/E
28.5xB
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
CDNA
NBIX
71% above
Price vs fair valuelower is cheaper
4% below
~28%/yr
Growth the price implies10-yr FCF · lower = less priced in
~13%/yr
-53%
1-yr DCF upside
-20%
-42%
5-yr DCF upside
+5%
-22%
10-yr DCF upside
+56%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
CDNA
Why this score
- Buying back stock
NBIX
Why this score
- Durable high returns
The companies
CDNACareDx, Inc.
Why now
Diagnostics & Research · market cap $2.0b. 6% off the 52-week high of $40.47. Revenue growing +34% — in hypergrowth territory. 5 sell-side analysts rate this a Buy with a mean 1-yr target of $35.40 (implying -7% upside).
Moat
Net margin 24% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 26% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which.
Risk
Beta 2.43 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return.
NBIXNeurocrine Biosciences, Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $18.7b. Trading near 52-week high of $186.12 — momentum setup, limited technical margin of safety. Revenue growing +29% — in hypergrowth territory. PEG 0.51 — paying under fair value for the growth rate. 27 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $202.17 (implying +9% upside).
Moat
Net margin 22% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 20% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 124% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trading within 0% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.